Chemotherapy-induced nausea and vomiting: can we do better?

Area of Science:

• Oncology
• Pharmacology
• Patient Care

Background:

• Chemotherapy-induced nausea and vomiting (CINV) management has advanced, yet significant challenges persist.
• Evolving antiemetic drug development necessitates updated treatment protocols.
• Current guidelines show suboptimal knowledge and adherence among healthcare providers.

Purpose of the Study:

• To review current challenges in CINV management.
• To provide updated guideline recommendations for emesis control.
• To enhance patient care strategies for managing nausea and vomiting during cancer treatment.

Main Methods:

• Literature review of recent advancements in antiemetics and CINV management.
• Analysis of risk factors associated with different anticancer regimens.
• Evaluation of current clinical practice guidelines and their compliance.

Main Results:

• New antiemetics offer improved efficacy, requiring tailored indications based on regimen and patient risk.
• Nausea, a subjective symptom, may benefit from enhanced patient education and evaluation methods.
• The impact of emesis extends beyond five days, necessitating adapted antiemetic prophylaxis and considering drug administration routes.

Conclusions:

• Updated guidelines are crucial for improving the management of emesis in cancer patients.
• Addressing persistent issues in CINV prevention and management requires continuous education and dissemination efforts.
• Integrating risk assessment and considering long-term emesis impact are vital for optimizing patient outcomes.